Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | M6223 |
Trade Name | |
Synonyms | M-6223|M 6223 |
Drug Descriptions |
M6223 targets and binds to TIGIT on immune cells, including tumor-infiltrating lymphocytes, and prevents its interaction with CD112 and CD155, thereby leading to enhanced interaction of CD112 and CD155 with CD226 expressed on natural killer and CD8 T+ cells, which may lead to the activation of anti-tumor immune responses (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C173891 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Avelumab + M6223 | Avelumab M6223 | 0 | 1 |
Bintrafusp alfa + M6223 | Bintrafusp alfa M6223 | 0 | 1 |
M6223 | M6223 | 0 | 1 |